Literature DB >> 10688652

Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis.

T Otsuka1, J Jakubczak, W Vieira, D P Bottaro, D Breckenridge, W J Larochelle, G Merlino.   

Abstract

Hepatocyte growth factor/scatter factor (HGF/SF) stimulates numerous cellular activities capable of contributing to the metastatic phenotype, including growth, motility, invasiveness, and morphogenetic transformation. When inappropriately expressed in vivo, an HGF/SF transgene induces numerous hyperplastic and neoplastic lesions. NK1 and NK2 are natural splice variants of HGF/SF; all interact with a common receptor, Met. Although both agonistic and antagonistic properties have been ascribed to each isoform in vitro, NK1 retains the full spectrum of HGF/SF-like activities when expressed as a transgene in vivo. Here we report that transgenic mice broadly expressing NK2 exhibit none of the phenotypes characteristic of HGF/SF or NK1 transgenic mice. Instead, when coexpressed in NK2-HGF/SF bitransgenic mice, NK2 antagonizes the pathological consequences of HGF/SF and discourages the subcutaneous growth of transplanted Met-containing melanoma cells. Remarkably, the metastatic efficiency of these same melanoma cells is dramatically enhanced in NK2 transgenic host mice relative to wild-type recipients, rivaling levels achieved in HGF/SF and NK1 transgenic hosts. Considered in conjunction with reports that in vitro NK2 induces scatter, but not other activities, these data strongly suggest that cellular motility is a critical determinant of metastasis. Moreover, our results demonstrate how alternatively structured ligands can be exploited in vivo to functionally dissociate Met-mediated activities and their downstream pathways.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10688652      PMCID: PMC110822          DOI: 10.1128/MCB.20.6.2055-2065.2000

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  74 in total

Review 1.  Hepatocyte growth factor--scatter factor: mitogen, motogen, and met.

Authors:  E Gherardi; M Stoker
Journal:  Cancer Cells       Date:  1991-06

Review 2.  The structures of domains of blood proteins.

Authors:  A Tulinsky
Journal:  Thromb Haemost       Date:  1991-07-12       Impact factor: 5.249

3.  Identification of a competitive HGF antagonist encoded by an alternative transcript.

Authors:  A M Chan; J S Rubin; D P Bottaro; D W Hirschfield; M Chedid; S A Aaronson
Journal:  Science       Date:  1991-11-29       Impact factor: 47.728

4.  Characterization of the DNF15S2 locus on human chromosome 3: identification of a gene coding for four kringle domains with homology to hepatocyte growth factor.

Authors:  S Han; L A Stuart; S J Degen
Journal:  Biochemistry       Date:  1991-10-08       Impact factor: 3.162

5.  Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor.

Authors:  S Rong; M Bodescot; D Blair; J Dunn; T Nakamura; K Mizuno; M Park; A Chan; S Aaronson; G F Vande Woude
Journal:  Mol Cell Biol       Date:  1992-11       Impact factor: 4.272

6.  A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis.

Authors:  G Hartmann; L Naldini; K M Weidner; M Sachs; E Vigna; P M Comoglio; W Birchmeier
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

7.  Functional characterization of human hepatocyte growth factor mutants obtained by deletion of structural domains.

Authors:  M Okigaki; M Komada; Y Uehara; K Miyazawa; N Kitamura
Journal:  Biochemistry       Date:  1992-10-13       Impact factor: 3.162

8.  The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors.

Authors:  M Prat; R P Narsimhan; T Crepaldi; M R Nicotra; P G Natali; P M Comoglio
Journal:  Int J Cancer       Date:  1991-09-30       Impact factor: 7.396

9.  Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET.

Authors:  L Naldini; E Vigna; R P Narsimhan; G Gaudino; R Zarnegar; G K Michalopoulos; P M Comoglio
Journal:  Oncogene       Date:  1991-04       Impact factor: 9.867

10.  An alternatively processed mRNA generated from human hepatocyte growth factor gene.

Authors:  K Miyazawa; A Kitamura; D Naka; N Kitamura
Journal:  Eur J Biochem       Date:  1991-04-10
View more
  15 in total

Review 1.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

2.  Overexpression of NK2 inhibits liver regeneration after partial hepatectomy in mice.

Authors:  Toshiyuki Otsuka; Norio Horiguchi; Daisuke Kanda; Takashi Kosone; Yuichi Yamazaki; Kazuhisa Yuasa; Naondo Sohara; Satoru Kakizaki; Ken Sato; Hitoshi Takagi; Glenn Merlino; Masatomo Mori
Journal:  World J Gastroenterol       Date:  2005-12-21       Impact factor: 5.742

3.  Structural basis for agonism and antagonism of hepatocyte growth factor.

Authors:  W David Tolbert; Jennifer Daugherty-Holtrop; Ermanno Gherardi; George Vande Woude; H Eric Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

4.  SF/HGF-c-Met autocrine and paracrine promote metastasis of hepatocellular carcinoma.

Authors:  Q Xie; K D Liu; M Y Hu; K Zhou
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

Review 5.  MET molecular mechanisms and therapies in lung cancer.

Authors:  Ryan E Lawrence; Ravi Salgia
Journal:  Cell Adh Migr       Date:  2010-01-16       Impact factor: 3.405

6.  Noncoding mutations of HGF are associated with nonsyndromic hearing loss, DFNB39.

Authors:  Julie M Schultz; Shaheen N Khan; Zubair M Ahmed; Saima Riazuddin; Ali M Waryah; Dhananjay Chhatre; Matthew F Starost; Barbara Ploplis; Stephanie Buckley; David Velásquez; Madhulika Kabra; Kwanghyuk Lee; Muhammad J Hassan; Ghazanfar Ali; Muhammad Ansar; Manju Ghosh; Edward R Wilcox; Wasim Ahmad; Glenn Merlino; Suzanne M Leal; Sheikh Riazuddin; Thomas B Friedman; Robert J Morell
Journal:  Am J Hum Genet       Date:  2009-07-02       Impact factor: 11.025

7.  Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects.

Authors:  Yu-An Yang; Oksana Dukhanina; Binwu Tang; Mizuko Mamura; John J Letterio; Jennifer MacGregor; Sejal C Patel; Shahram Khozin; Zi-Yao Liu; Jeffrey Green; Miriam R Anver; Glenn Merlino; Lalage M Wakefield
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

Review 8.  Hepatocyte growth factor and alternative splice variants - expression, regulation and implications in osteogenesis and bone health and repair.

Authors:  Rachel N Frisch; Kevin M Curtis; Kristina K Aenlle; Guy A Howard
Journal:  Expert Opin Ther Targets       Date:  2016-03-21       Impact factor: 6.902

9.  Expression array analysis of the hepatocyte growth factor invasive program.

Authors:  Fabiola Cecchi; Chih-Jian Lih; Young H Lee; William Walsh; Daniel C Rabe; Paul M Williams; Donald P Bottaro
Journal:  Clin Exp Metastasis       Date:  2015-08-01       Impact factor: 5.150

10.  Targeting the HGF-cMET Axis in Hepatocellular Carcinoma.

Authors:  Neeta K Venepalli; Laura Goff
Journal:  Int J Hepatol       Date:  2013-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.